Public Health, Nutrition & Epidemics20 Concepts & Facts

OneSCD Global Partnership GK Facts, Sickle Cell Care & Health Equity Guide

Reviewed by the Master10 Editorial Board for accuracy, clarity and competitive-exam relevance.Editorial Policy

Sickle Cell Disease is an inherited autosomal recessive hemoglobinopathy caused by a point mutation in the beta-globin gene, resulting in abnormal sickle-shaped red blood cells that trigger vaso-occlusive crises, hemolytic anemia, and cumulative end-organ damage. Globally, over eight million individuals live with the disorder, with disproportionate morbidity clustered across Sub-Saharan Africa, India, and parts of the Mediterranean and Middle East. Despite the substantial burden of disease, therapeutic access to disease-modifying agents such as hydroxyurea, universal neonatal screening, and pneumococcal prophylaxis has historically remained skewed toward high-income countries, leaving vulnerable populations facing severe premature mortality.

To bridge this profound global health equity divide, the international community launched the OneSCD initiative on September 23, 2026, during the high-level week of the 81st session of the United Nations General Assembly in New York. Titled 'OneSCD: A Global Partnership to Advance Equity and Transform Sickle Cell Care', the coalition was co-hosted by the Government of India alongside the Government of Nigeria, the World Health Organization, UNICEF, Africa CDC, the World Coalition on Sickle Cell Disease, and St. Jude Children’s Research Hospital. The partnership functions as a multilateral coordination mechanism designed to translate WHO clinical guidelines into funded national implementation plans, drive down the cost of point-of-care diagnostics, and secure sustainable access to quality therapeutics.

India’s co-leadership in OneSCD is deeply rooted in its domestic healthcare priorities under the National Sickle Cell Anaemia Elimination Mission, launched in July 2023 with the target of eliminating the disease as a public health challenge by 2047. The national mission focuses on screening seven crore individuals under forty years of age across seventeen high-prevalence states, distributing color-coded genetic status cards, and integrating premarital counseling within primary tribal healthcare centers. For public health and competitive examination aspirants, OneSCD operates as a model of South-South cooperation, global health diplomacy, genomic public policy, and universal health coverage implementation.

Key Concepts & Self-Assessment20 Key Facts

Review key OneSCD: Global Partnership to Advance Equity & Sickle Cell Disease Healthcare exam facts and rate your mastery to track revision.

Progress: 0/20 Rated 0 Mastered 0 Review Later

OneSCD is an international multilateral partnership launched on September 23, 2026, during the 81st UN General Assembly session in New York.

The official title of the initiative is 'OneSCD: A Global Partnership to Advance Equity and Transform Sickle Cell Care'.

The partnership was co-hosted by India, Nigeria, the World Health Organization, UNICEF, Africa CDC, and St. Jude Children's Research Hospital.

Sickle Cell Disease is an autosomal recessive genetic disorder caused by a single nucleotide mutation in the HBB gene on chromosome 11.

The point mutation substitutes valine for glutamic acid at the sixth position of the beta-globin protein subunit (Glu6Val).

Deoxygenated sickle hemoglobin polymerizes into rigid fibrous strands, transforming flexible biconcave erythrocytes into rigid, sickle-shaped cells.

Rigid sickle cells obstruct microvascular capillary beds, causing excruciating vaso-occlusive crises, acute chest syndrome, and organ infarction.

India represents the second-highest global burden of sickle cell disease after Sub-Saharan Africa, predominantly concentrated in tribal communities.

India launched the National Sickle Cell Anaemia Elimination Mission on July 1, 2023, from Shahdol district in Madhya Pradesh.

#10

The National Mission establishes an ambitious public health deadline to eliminate sickle cell disease as a national public health problem by 2047.

#11

The Indian mission targets universal screening of seven crore individuals aged up to forty years across seventeen high-burden states.

#12

Screening protocols utilize color-coded Sickle Cell Status Cards to distinguish between healthy individuals, asymptomatic carriers (HbAS), and diseased patients (HbSS).

#13

Hydroxyurea is the primary oral disease-modifying drug used to stimulate the synthesis of fetal hemoglobin (HbF), reducing vaso-occlusion.

#14

OneSCD seeks to lower the market pricing of affordable point-of-care solubility and electrophoresis test kits for resource-constrained clinics.

#15

The partnership facilitates global clinical trials and knowledge exchange on advanced curative therapies, including allogeneic bone marrow transplantation.

#16

CRISPR-Cas9 gene editing therapies (such as Exagamglogene autotemcel) represent revolutionary curative pathways by reactivating fetal hemoglobin.

#17

Repeated splenic sequestration and infarction in early childhood render sickle cell patients functionally asplenic, necessitating daily penicillin prophylaxis.

#18

OneSCD aligns directly with United Nations Sustainable Development Goal 3, target 3.8, concerning Universal Health Coverage and non-communicable diseases.

#19

South-South cooperation between India and African nations under OneSCD establishes joint genomic epidemiology databases and screening protocols.

#20

World Sickle Cell Day is observed globally every year on June 19, following United Nations General Assembly Resolution 63/237 adopted in 2008.

Subject Specialist Commentary

Analytical perspective & practical exam advice from the Master10 academic board

Educator's Insight

Sickle cell anemia is a hereditary blood condition that hits vulnerable tribal and rural communities hardest. Because abnormal hemoglobin warps red blood cells into stiff sickles, they get stuck in tiny blood vessels, causing severe pain and organ damage. The OneSCD initiative represents a major global breakthrough by uniting high-burden nations like India and Nigeria with the WHO to make lifesaving tests and medicines available to everyone, regardless of income.

In UPSC and State PSC exams, focus on the genetic mechanism and national health targets. Remember that SCD is autosomal recessive (both parents must carry the sickle gene trait for a child to develop full disease). Contrast the global OneSCD partnership with India's domestic National Sickle Cell Anaemia Elimination Mission, targeting 2047 for elimination. A classic MCQ trap: carriers with the sickle cell trait (HbAS) are largely asymptomatic and enjoy natural resistance against severe falciparum malaria.

OneSCD Global Partnership GK Facts, Sickle Cell Care & Health Equity Guide

Key Concepts & Self-Assessment20 Key Facts

Subject Specialist Commentary

Related Knowledge Topics to Discover

Looking for more GK practice?